Netherlands PLS Natural History Study 2025 — Implications for Diagnostic Criteria
Natural history evidence from a single country, or a single healthcare system, is always vulnerable to the question of generalizability. Do North American PLS patients — followed in NEALS academic centers — behave the same as European patients diagnosed within different healthcare structures, referral patterns, and diagnostic practices? The Netherlands natural history study provides an independent answer: largely yes, but with findings that push the field to reconsider specific aspects of the diagnostic criteria.
Background: why independent validation matters
The 2020 consensus criteria for PLS were developed primarily by North American and British researchers, validated against cohorts that included patients from those regions. The thresholds they established — particularly the 2-year "probable" and 4-year "definite" cutoffs — were based on prior natural history data that was itself drawn predominantly from North American centers.
Independent replication from a different healthcare system is important for two reasons. First, it tests whether the criteria generalize across different diagnostic practices, referral pathways, and patient populations. Second, prospective European cohort data adds to the cumulative evidence base and can identify where the criteria may need refinement.
The Netherlands is a particularly useful setting for this validation: it has a well-organized national neurology network, relatively high rates of specialist care access, and a tradition of prospective MND registry maintenance. Multiple Dutch centers contributed to this cohort.
What they did
Dutch researchers prospectively followed a national cohort of patients with PLS or suspected PLS at multiple centers. The study was designed to generate natural history data and to specifically evaluate how the 2020 consensus criteria performed in a real-world population — not just in the expert-center cohort for which the criteria were originally developed.
Patients were enrolled at the point of clinical suspicion of PLS and followed over time, with systematic documentation of functional status, presence or absence of lower motor neuron signs, and clinical trajectory. The study assessed both whether the criteria correctly identified patients who maintained a pure PLS course and whether the diagnostic thresholds appropriately excluded those who converted to ALS.
What they found
Broad consistency with prior cohorts
The prospective Dutch cohort data was broadly consistent with North American and British findings on rate of functional decline and survival. Patients who met criteria for probable or definite PLS showed the characteristically slow progression described in the NEALS Consortium data and the Oxford SCNI cohort — decline measured in fractions of ALSFRS-R points per year rather than the 4–6 points per year typical of ALS. This cross-national consistency is clinically meaningful: it strengthens the conclusion that PLS is a biologically consistent entity with a predictable trajectory, not a heterogeneous category that varies dramatically by geography or healthcare context.
Implications for diagnostic thresholds
The study's contribution to the criteria debate centers on the question of whether the current thresholds — particularly the 4-year "definite PLS" boundary — remain optimal given improving biomarker differentiation. The Dutch data contributes to a growing international conversation about whether the waiting period could be shortened without meaningfully increasing misclassification rates. The argument is that as neuroimaging, EMG, and fluid biomarker techniques improve, it may be possible to confidently distinguish PLS from ALS earlier than 4 years from symptom onset.
The study did not find that the 2020 criteria were wrong — it found that they performed reasonably in a European population — but it identified specific areas where prospective data suggests refinement may be warranted. This is a contribution to an ongoing international discussion rather than a call for immediate criteria revision.
Conversion rates in the Dutch cohort
The data on conversion from probable PLS to ALS in the Dutch cohort was consistent with prior estimates of approximately 23% within the first 4 years. This figure — which is the biological justification for the 4-year diagnostic threshold — held up in an independent European population, strengthening confidence that it reflects a genuine feature of PLS disease biology rather than a selection artifact of American academic centers.
Why it matters
Independent replication is foundational to medical evidence. The fact that North American and Dutch cohorts show broadly consistent natural history — similar rates of decline, similar conversion proportions, similar survival patterns — is exactly the kind of cross-national validation that the PLS evidence base needed.
For the diagnostic criteria specifically, this study adds weight to the argument that the 2020 criteria are ready for routine clinical use outside the expert centers where they were developed. It also contributes to the evidence base for future criteria revision, which the field is already discussing in the context of improving biomarker capabilities.
For patients in Europe — particularly the Netherlands and surrounding countries — this study also demonstrates that PLS is being taken seriously as a subject of dedicated prospective research, not just as a subgroup of ALS registries.
How this connects
This study directly tests and validates the 2020 consensus criteria. Its natural history findings are consistent with both Gordon 2006 and the PNHS Mayo Clinic study, strengthening the cross-national evidence base. The conversion rate data it confirms underpins the diagnostic timeline discussed on the Diagnosis page. The broader natural history synthesis is on the Natural History hub.
Citation
Netherlands PLS natural history consortium. Primary lateral sclerosis: implications for diagnostic criteria refinement. PubMed Central (PMC). 2025. [PMC identifier pending full citation confirmation]